Evidence map›Paper›PMID 30048623›Full record

ReviewChemico-biological interactions2018

Toxicological status of nanoparticles: What we know and what we don't know.

Wided N Missaoui, Robert D Arnold, Brian S Cummings

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Chemico-biological interactions, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Analyzing Molecular Determinants of Nanodrugs' Cytotoxic Effects.International journal of molecular sciences · 2025
    Pooled it
  3. Advances in Nanotoxicology: Health and Safety.Nanomaterials (Basel, Switzerland) · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. [The application of nanoparticles in the treatment and prevention of pathological scars].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2026
    Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Wided N MissaouiDept. of Pharmaceutical and Biomedical Sciences, College of Pharmacy, University of Georgia, Athens, GA, USA.
Robert D ArnoldDepartment of Drug Discovery & Development, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA.
Brian S CummingsInterdisciplinary Toxicology Program, University of Georgia, Athens, GA, USA. Electronic address: briansc@uga.edu.

Funding

Secretory Phospholipases sPLA2 and their Receptors for Delivering NanoparticlesR01EB016100 · NIBIB · AUBURN UNIVERSITY AT AUBURN · PI ARNOLD, ROBERT D · 2013 to 2016
$1.3M
NIBIB NIH HHS R01 EB016100
6 · The paper itself

Abstract

The field of nanotechnology has grown exponentially during the last few decades, due in part to the use of nanoparticles in many manufacturing processes, as well as their potential as clinical agents for treatment of diseases and for drug delivery. This has created several new avenues by which humans can be exposed to nanoparticles. Unfortunately, investigations assessing the toxicological impacts of nanoparticles (i.e. nanotoxicity), as well as their possible risks to human health and the environment, have not kept pace with the rapid rise in their use. This has created a gap-in-knowledge and a substantial need for more research. Studies are needed to help complete our understanding of the mechanisms of toxicity of nanoparticles, as well as the mechanisms mediating their distribution and accumulation in cells and tissues and their elimination from the body. This review summarizes our knowledge on nanoparticles, including their various applications, routes of exposure, their potential toxicity and risks to human health.

Indexed as

Drug Delivery SystemsHumansNanoparticlesNanotechnologyCell deathDrug deliveryNanoparticlesNanotoxicologyToxicology

Identifiers

PMID30048623
PMCPMC8427273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.